"Many large Pharmaceutical companies are developing small molecule inhibitors of Shh signalling, although the majority are focussed on a single target in the pathway ?
Smoothened (Figure 3). Phylogica is aiming to exploit this situation by undertaking simultaneous screens against multiple targets in the hedgehog pathway. We have already initiated screens against various targets in the Shh pathway, including Smoothened, which have yielded over 50 potential leads.
Moreover, we have entered into a collaboration with researchers at the Telethon Institute of Child Health Research in Perth, who are developing various animal models that can be used to validate the biological activity of the various sonic hedgehog-specific Phylogica hits. By so doing, Phylogica aims to highlight the power of its drug discovery engine to rapidly identify leads against high value commercial targets."
PYC Price at posting:
5.7¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)